Global $1.8 Billion Rare Disease Genetic Testing Market to 2027: Focused Approach of Key Market Players on Cost-Effective Treatments are Driving Growth

DUBLIN, March 2, 2021 The "Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type; By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027

The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player's in cost-effective treatments are the key factors responsible for market growth.

Moreover, government-sponsored schemes are also expected to positively impact the market. In February 2020, the government of India announced financial assistance of INR 15 lacs to the patients suffering from uncommon ailments under the Rashtriya Arogaya Nidhi scheme for a one-time treatment.

The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region. In terms of disease type, the market is segmented into neurological disorders, immunological disorders, hematology illnesses, endocrine & metabolism ailments, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology illnesses, and others.

Based on technology, the rare disease genetic testing industry is further bifurcated into next-generation sequencing, array technology, PCR-based testing, FISH, sanger sequencing, and karyotyping. Based on specialty, the rare disease genetic testing industry is further bifurcated into molecular, chromosomal, and biochemical genomic tests. Based on end-use, the rare disease genomic testing industry is further bifurcated into research laboratories & CROs, hospitals & clinics, and diagnostic laboratories.

Segment Highlights

• Neurological ailments accounted for the largest revenue share in 2019 on account of the increasing prevalence of neurologic disorders across the globe and presence of numerous testing techniques.
• Based on technology, the next generation sequencing segment is projected to constitute almost half of the market in 2027. The usage of the technology in whole genome sequencing is the key factor responsible for its segment's growth.
• Molecular tests are expected to account for the highest revenue share by the end of 2027. The availability of advanced technologies and ability to test ultra-rare disorders is expected to drive market growth.
• Research laboratories & CROs accounted for the largest revenue share in 2019 owing to the increasing number of tests and growing occurrence of rare disorders across the developed economies.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Rare Disease Genetic Testing Market Insights
4.1. Rare Disease Genetic Testing - Industry snapshot
4.2. Rare Disease Genetic Testing Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Prevalence of rare diseases
4.2.1.2. Government backed funding
4.2.2. Restraints and Challenges
4.2.2.1. Lack of epidemiological data
4.3. Porter's Five Forces Analysis
4.4. PESTLE Analysis
4.5. Rare Disease Genetic Testing Market Industry trends

5. Rare Disease Genetic Testing Market Assessment by Disease Type
5.1. Key Findings
5.2. Introduction
5.3. Neurological Disorders
5.4. Immunological Disorders
5.5. Hematology Diseases
5.6. Endocrine & Metabolism Diseases
5.7. Cancer
5.8. Musculoskeletal Disorders
5.9. Cardiovascular Disorders
5.10. Dermatology Diseases

6. Global Rare Disease Genetic Testing Market, by Technology
6.1. Key Findings
6.2. Introduction
6.3. Next Generation Sequencing
6.3.1. Global Rare Disease Genetic Testing Market, by Next Generation Sequencing, By Region, 2016- 2027 (USD Million)
6.3.2. Whole Exome Sequencing
6.3.3. Whole Genome Sequencing
6.4. Array Technology
6.5. PCR - based Testing
6.6. FISH
6.7. Sanger Sequencing
6.8. Karyotyping

7. Global Rare Disease Genetic Testing Market, by Specialty
7.1. Key Findings
7.2. Introduction
7.3. Molecular Genetic Testing
7.4. Chromosomal Genetic Testing
7.5. Biochemical Genetic Tests

8. Rare Disease Genetic Testing Market Assessment by End Use
8.1. Key Findings
8.2. Introduction
8.3. Research Laboratories & CROs
8.4. Hospitals & Clinics
8.5. Diagnostic Laboratories

9. Rare Disease Genetic Testing Market Assessment by Geography
9.1. Key findings
9.2. Introduction

10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles
11.1. Company Overview
11.2. Financial Performance
11.3. Services/Product Benchmarking
11.4. Recent Developments

• Strand Life Sciences
• Myriad Genetics
• Quest Diagnostics Inc.
• Centogene N.V.
• Invitae Corporation
• 3billion Inc.
• Eurofins Scientific
• Baylor Genetics
• Ambry Genetics
• Perkin Elmer
• Macrogen Inc.
• Opko Health Inc.
• Color Genomics Inc.
• Health Network Laboratories
• Preventiongenetics
• Progenity Inc.
• Fulgent Genetics Inc.
• Laboratory Corporation of America Holdings

For more information about this report visit https://www.researchandmarkets.com/r/vmtf66

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-1-8-billion-rare-disease-genetic-testing-market-to-2027-focused-approach-of-key-market-players-on-cost-effective-treatments-are-driving-growth-301238859.html

SOURCE Research and Markets